Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Aims: GLP-1 receptor agonists, such as semaglutide (Ozempic) and tirzepatide (Monjaro), have gained significant popularity for obesity management, but concerns have arisen about their potential link to thyroid cancer. This study investigates the association between thyroid cancer and weight-loss medications.

Materials And Methods: A disproportionality analysis was conducted using data from the FDA Adverse Event Reporting System (FAERS) from 2004 to Q1 2024. Reporting odds ratios (RORs) were used to identify associations between thyroid cancer and weight-loss drugs, including anti-diabetic medications.

Results: Significant positive associations with thyroid cancer were found for GLP-1 receptor agonists: semaglutide (ROR = 7.61, 95% CI: 6.37-9.08), dulaglutide (ROR = 3.59, 95% CI: 3.03-4.27), liraglutide (ROR = 15.59, 95% CI: 13.94-17.44) and tirzepatide (ROR = 2.09, 95% CI: 1.51-2.89). A weak inverse association was observed for metformin (ROR = 0.58, 95% CI: 0.36-0.93). No significant associations were found for other drugs, such as topiramate, dapagliflozin and insulin glargine.

Conclusion: The study, based on data from the FAERS database, suggests a potential association between GLP-1 receptor agonists and an increased thyroid cancer risk. These findings underscore the importance of further research and continuous safety monitoring when prescribing these medications for obesity management.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889434PMC
http://dx.doi.org/10.1002/edm2.70038DOI Listing

Publication Analysis

Top Keywords

thyroid cancer
24
glp-1 receptor
12
receptor agonists
12
fda adverse
8
adverse event
8
event reporting
8
reporting system
8
agonists semaglutide
8
obesity management
8
cancer weight-loss
8

Similar Publications

Pyrotinib versus Pertuzumab with Trastuzumab and Taxane in HER2-Positive Metastatic Breast Cancer: A Chinese Multicenter Real-world Study.

Oncologist

September 2025

Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.

Background: THP (trastuzumab + paclitaxel + pertuzumab) and THPy (trastuzumab + paclitaxel + pyrotinib) are widely used as first-line regimens for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) in China. However, direct comparative data on their efficacy and safety remain scarce. This study evaluates and compares the clinical outcomes of THPy and THP in the first-line treatment of HER2-positive MBC to guide clinical decision-making.

View Article and Find Full Text PDF

The spindle cell variant of papillary thyroid carcinoma (PTC) is exceptionally rare and poses significant diagnostic challenges due to its morphological overlap with other spindle cell lesions of the thyroid. We report a novel case of spindle cell variant PTC in a 66-year-old woman presenting with a TI-RADS 4 thyroid nodule, initially classified as Bethesda III on fine-needle aspiration. Histopathological examination revealed a biphasic tumor composed predominantly of bland spindle cells arranged in solid sheets and fascicles, admixed with entrapped thyroid follicles.

View Article and Find Full Text PDF

It has been reported that DNA methylation in the epigenetic profile of the genes LEP and ADIPOQ is associated with obesity. To the best of our knowledge, there are no previous reports assessing the methylation of the LEP, LEPR, and ADIPOQ genes in subjects with metabolically healthy obesity (MHO). Therefore, the aim of this study was to determine the association between methylation of the LEP, LEPR, and ADIPOQ genes with the MHO phenotype.

View Article and Find Full Text PDF

Rationale: Brown tumor (osteitis fibrosa cystica) is a benign bone lesion associated with hyperparathyroidism that can affect multiple bones in patients with end-stage renal disease (ESRD).

Patient Concerns: We present the case of a 32-year-old female with ESRD on maintenance hemodialysis who experienced body aches, muscle weakness, constipation, and mood swings for 3 months.

Diagnoses: Initial tests revealed elevated parathyroid hormone (PTH), serum calcium, and phosphorus levels.

View Article and Find Full Text PDF

Objectives: Serum thyroglobulin (Tg) is a key biomarker in the post-surgical monitoring of differentiated thyroid cancer (DTC). However, inter-assay variability among different immunoassay platforms can impact clinical interpretation, particularly at low Tg concentrations. This study aimed to compare the analytical performance and concordance of three widely used Tg immunoassays, Access (Beckman Coulter, Tg-B), Atellica (Siemens, Tg-A), and Liaison (Diasorin, Tg-L), with a focus on their agreement across clinically relevant Tg ranges.

View Article and Find Full Text PDF